Clinical evidence and mechanistic basis for vildagliptin's effect in combination with insulin

Vascular Health and Risk Management

Volumn 9, Issue 1, 2013, Pages 57-64

  Schweizer, Anja ^a   Foley, James E ^a   Kothny, Wolfgang ^a   Ahrén, Bo ^b  

^a NOVARTIS PHARMA AG   (Switzerland)

^b LUND UNIVERSITY   (Sweden)

Author keywords

DPP 4; GIP; GLP 1; Hypoglycemia; Incretin; Insulin therapy; Type 2 diabetes

Indexed keywords

DIPEPTIDYL PEPTIDASE IV; GLUCAGON; GLUCAGON LIKE PEPTIDE 1; GLUCOSE; HEMOGLOBIN A1C; INSULIN; METFORMIN; PLACEBO; VILDAGLIPTIN;

DISEASE COURSE; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HUMAN; HYPOGLYCEMIA; INSULIN TREATMENT; NON INSULIN DEPENDENT DIABETES MELLITUS; PROTECTION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SIDE EFFECT; WEIGHT GAIN;

DPP-4; GIP; GLP-1; HYPOGLYCEMIA; INCRETIN; INSULIN THERAPY; TYPE 2 DIABETES;

ADAMANTANE; BIOLOGICAL MARKERS; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; DRUG THERAPY, COMBINATION; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; INSULIN; NITRILES; PYRROLIDINES; TREATMENT OUTCOME; WEIGHT GAIN;

EID: 84879186130     PISSN: 11766344     EISSN: 11782048     Source Type: Journal    
DOI: 10.2147/VHRM.S40972     Document Type: Review

References (37)

1. UK Prospective Diabetes Study Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998;352:837-853.
2. Colwell JA. Intensive insulin therapy in type II diabetes: rationale and collaborative clinical trial results. Diabetes. 1996;45(Suppl 3): S87-S90.
3. Turner RC, Holman RR. Lessons from UK prospective diabetes study. Diabetes Res Clin Pract. 1995;28(Suppl):S151-S157.
4. Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329:977-986.
5. Janka HU, Plewe G, Riddle MC, Kliebe-Frisch C, Schweitzer MA, Yki-Jarvinen H. Comparison of basal insulin added to oral agents versus twice-daily premixed insulin as initial insulin therapy for type 2 diabetes. Diabetes Care. 2005;28:254-259.
6. Peters KR. Intensifying treatment of type 2 diabetes mellitus: adding insulin. Pharmacotherapy. 2011;31:54S-64S.
7. Raskin P. Why insulin sensitizers but not secretagogues should be retained when initiating insulin in type 2 diabetes. Diabetes Metab Res Rev. 2008;24:3-13.
8. Yki-Jarvinen H. Combination therapies with insulin in type 2 diabetes. Diabetes Care. 2001;24:758-767.
9. Swinnen SG, Dain M P, Mauricio D, Devries JH, Hoekstra JB, Holleman F. Continuation versus discontinuation of insulin secretagogues when initiating insulin in type 2 diabetes. Diabetes Obes Metab. 2010;12: 923-925.
10. He YL, Serra D, Wang Y et al. Pharmacokinetics and pharmacodynamics of vildagliptin in patients with type 2 diabetes mellitus. Clin Pharmacokinet. 2007;46:577-588.
11. Rosenstock J, Foley JE, Rendell M, et al. Effects of the dipeptidyl peptidase-IV inhibitor vildagliptin on incretin hormones, islet function, and postprandial glycemia in subjects with impaired glucose tolerance. Diabetes Care. 2008;31:30-35.
12. Ahren B, Schweizer A, Dejager S, Villhauer EB, Dunning BE, Foley JE. Mechanisms of Action of the DPP-4 Inhibitor Vildagliptin in Man. Diabetes Obes Metab. 2011;13:775-783.
13. Monnier L, Colette C. Contributions of fasting and postprandial glucose to hemoglobin A1c. Endocr Pract. 2006;12(Suppl 1):42-46.
14. Rodbard H W, Jellinger PS, Bloomgarden ZT. AACE/ACE glycemic control algorithm consensus panel. Endocr Pract. 2009;15: 541-559.
15. Ahluwalia R, Vora J. Emerging role of insulin with incretin therapies for management of type 2 diabetes. Diabetes Ther. 2011;2:146-161.
16. Rizos EC, Ntzani EE, Papanas N, et al. Combination Therapies of DPP4 Inhibitors and GLP1 Analogues with Insulin in Type 2 Diabetic Patients: A Systematic Review. Curr Vasc Pharmacol. Epub 2012 Jun 22.
17. Schweizer A, Dejager S, Foley JE. Impact of insulin resistance, body mass index, disease duration, and duration of metformin use on the efficacy of vildagliptin. Diabetes Ther. 2012;3:8.
18. Cryer PE. Hypoglycaemia: the limiting factor in the glycaemic management of Type I and Type II diabetes. Diabetologia. 2002;45: 937-948.
19. Christensen M, Vedtofte L, Holst JJ, Vilsboll T, Knop FK. Glucose-dependent insulinotropic polypeptide: a bifunctional glucose-dependent regulator of glucagon and insulin secretion in humans. Diabetes. 2011;60:3103-3109.
20. Fonseca V, Schweizer A, Albrecht D, Baron MA, Chang I, Dejager S. Addition of vildagliptin to insulin improves glycaemic control in type 2 diabetes. Diabetologia. 2007;50:1148-1155.
21. Fonseca V, Baron M, Shao Q, Dejager S. Sustained efficacy and reduced hypoglycemia during one year of treatment with vildagliptin added to insulin in patients with type 2 diabetes mellitus. Horm Metab Res. 2008;40:427-430.
22. Kothny W, Foley J, Kozlovski P, Shao Q, Gallwitz B, Lukashevich V. Improved glycaemic control with vildagliptin added to insulin, with or without metformin, in patients with type 2 diabetes mellitus. Diabetes Obes Metab. 2013;15:252-257.
23. Lukashevich V, Schweizer A, Shao Q, Groop PH, Kothny W. Safety and efficacy of vildagliptin versus placebo in patients with type 2 diabetes and moderate or severe renal impairment: a prospective 24-week randomized placebo-controlled trial. Diabetes Obes Metab. 2011;13:947-954.
24. Lukashevich V, Schweizer A, Foley JE, Dickinson S, Groop PH, Kothny W. Efficacy of vildagliptin in combination with insulin in patients with type 2 diabetes and severe renal impairment. Vasc Health Risk Manag. 2013;9:21-28.
25. Ligueros-Saylan M, Foley JE, Schweizer A, Couturier A, Kothny W. An assessment of adverse effects of vildagliptin versus comparators on the liver, the pancreas, the immune system, the skin and in patients with impaired renal function from a large pooled database of Phase II and III clinical trials. Diabetes Obes Metab. 2010;12:495-509.
26. Schweizer A, Dejager S, Foley JE, Kothny W. Assessing the general safety and tolerability of vildagliptin: value of pooled analyses from a large safety database versus evaluation of individual studies. Vasc Health Risk Manag. 2011;7:49-57.
27. Ved P, Shah S. Evaluation of vildagliptin and fxed dose combination of vildagliptin and metformin on glycemic control and insulin dose over 3 months in patients with type 2 diabetes mellitus. Indian J Endocrinol Metab. 2012;16(Suppl 1):S110-S113.
28. Bertoldo A, Pencek RR, Azuma K, et al. Interactions between delivery, transport, and phosphorylation of glucose in governing uptake into human skeletal muscle. Diabetes. 2006;55:3028-3037.
29. Pencek RR, Bertoldo A, Price J, Kelley C, Cobelli C, Kelley DE. Dose-responsive insulin regulation of glucose transport in human skeletal muscle. Am J Physiol Endocrinol Metab. 2006;290:E1124-E1130.
30. Cryer PE. Hypoglycemia: still the limiting factor in the glycemic management of diabetes. Endocr Pract. 2008;14:750-756.
31. Cryer PE. The barrier of hypoglycemia in diabetes. Diabetes. 2008;57:3169-3176.
32. Ahren B, Holst JJ, Mari A. Characterization of GLP-1 effects on beta-cell function after meal ingestion in humans. Diabetes Care. 2003;26: 2860-2864.
33. Holst JJ, Christensen M, Lund A, et al. Regulation of glucagon secretion by incretins. Diabetes Obes Metab. 2011;13(Suppl 1):89-94.
34. Ahren B, Schweizer A, Dejager S, et al. Vildagliptin enhances islet responsiveness to both hyper- and hypoglycemia in patients with type 2 diabetes. J Clin Endocrinol Metab. 2009;94:1236-1243.
35. Foley JE, Ligueros-Saylan M, He YL, et al. Effect of vildagliptin on glucagon concentration during meals in patients with type 1 diabetes. Horm Metab Res. 2008;40:727-730.
36. Ferrannini E, Groop PH, Nauck M, Fioretto P, Hach T, Thomas M. The Signifcance of the Kidney in Diabetes. Konigswinter, Germany: infll Kommunikation GmbH; 2012.
37. Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia. 2012;55:1577-1596.